Facebook’s CFO Is Trying to Cure Alzheimer’s Disease by Doing This

Facebook’s CFO David Wehner has joined his first board outside of the social media platform.

Wehner has joined the board of a biotech company called Alector that is pursuing a novel approach to treating Alzheimer’s Disease.

The South San Francisco-based company, founded in 2013, has also recruited two other board members; the former CFO of Genentech and Richard Scheller, the chief scientific officer of 23andMe. Considering that one is a former CFO and the other is a current CFO, there may be an IPO on the horizon.

“We look forward to leveraging their insights in drug development, strategic financial management, business operations and corporate growth strategies in order to accelerate transformative medicines with the goal of curing neurodegenerative diseases,” said Arnon Rosenthal, Alector’s CEO, in a statement.
Alzheimer’s Disease currently has no cure and affects 5 million Americans.

According to Alector’s website, the company mines the human genome to identify mutations in immune system genes that increase the risk for these disorders. From there, the company pioneers new drugs that counteract the damage these mutations cause.

Disclaimer: We have no position in Facebook, Inc. Common Stock (NASDAQ: FB) and have not been compensated for this article.